Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke

References

• Carod-Artal FJ. Trypanosomiasis. In: International Neurology, A Clinical Approach (1st Edition). Lisak R, Truong D, Carroll W, Bhidayasiri R (Eds). John Wiley & Sons, Oxford, UK, 290–292 (2009).
   Google Scholar
• Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 17–30 (2009).
   PubMed Web of Science ®Google Scholar
• Mathers CD, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl. Trop. Dis.1, e114 (2007).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. Stroke in central nervous system infections. Ann. Indian Acad. Neurol.11, 64–78 (2008).
   Google Scholar
• Araujo A, Jansen AM, Reinhard K, Ferreira LF. Paleoparasitology of Chagas disease – a review. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 9–16 (2009).
   PubMedGoogle Scholar
• WHO. Global burden of disease estimates: 2004 update. WHO, Geneva, Switzerland (2008).
   Google Scholar
• Carod-Artal FJ. Strokes caused by infection in the tropics. Rev. Neurol.44(12), 755–763 (2007).
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Dias JC. The Southern Cone Initiative against Chagas disease. Adv. Parasitol.42, 1–27 (1999).
   PubMed Web of Science ®Google Scholar
• Guhl F, Pinto N, Aguilera G. Sylvatic triatominae: a new challenge in vector control transmission. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 71–75 (2009).
   PubMedGoogle Scholar
• Carod Artal FJ. Bolivia. In: Mosby’s Pocket Guide to Cultural Health Assessment (4th Edition). D’Avanzo C (Ed.). 83–88 (2008).
   Google Scholar
• Higo H, Miura S, Horio M et al. Genotypic variation among lineages of Trypanosoma cruzi and its geographic aspects. Parasitol. Int.53, 337–344 (2004).
   PubMed Web of Science ®Google Scholar
• Sánchez Negrete O, Mora MC, Basombrío MA. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics115, 668–672 (2005).
   Google Scholar
• Nóbrega AA, Garcia MH, Tatto E et al. Oral transmission of Chagas disease by consumption of açaí palm fruit, Brazil. Emerg. Infect. Dis.15, 653–655 (2009).
   PubMed Web of Science ®Google Scholar
• Valente SA, da Costa Valente V, das Neves Pinto AY et al. Analysis of an acute Chagas disease outbreak in the Brazilian Amazon: human cases, triatomines, reservoir mammals and parasites. Trans. R. Soc. Trop. Med. Hyg.103, 291–297 (2009).
   PubMed Web of Science ®Google Scholar
• Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. DOI: 10.1016/j.actatropica.2009.11.003 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis.49, e52–e54 (2009).
   PubMed Web of Science ®Google Scholar
• Milei J, Guerri-Guttenberg RA, Grana DR, et al. Prognostic impact of Chagas disease in the United States. Am. Heart. J.157, 22–29 (2009).
   PubMed Web of Science ®Google Scholar
• Hanford EJ, Zhan FB, Lu Y, Giodano A. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc. Sci. Med.65, 60–79 (2007).
   PubMed Web of Science ®Google Scholar
• Bowling J, Walter EA. Recognizing and meeting the challenge of Chagas disease in the USA. Expert Rev. Anti. Infect. Ther.7(10), 1223–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Yadon ZE, Schmunis GA. Congenital Chagas disease: estimating the potential risk in the United States. Am. J. Trop. Med. Hyg.81(6), 927–933 (2009).
   PubMed Web of Science ®Google Scholar
• Piron M, Vergés M, Muñoz J et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion48, 1862–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Muñoz J, Coll O, Juncosa T et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin. Infect. Dis.48(12), 1736–1740 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez de Tejada B, Jackson Y, Paccolat C, Irion O; Groupe Chagas Congénital Genéve. Congenital Chagas disease in Geneva: diagnostic and clinical aspects. Rev. Med. Suisse5, 2094–2096 (2009).
   Google Scholar
• Barr SC. Canine Chagas’ disease (American trypanosomiasis) in North America. Vet. Clin. North Am. Small Anim. Pract.39, 1055–1064 (2009).
   PubMedGoogle Scholar
• No authors listed. Chagas disease: the forgotten American neuroinfection. Lancet Neurol.8, 501 (2009).
   PubMedGoogle Scholar
• Otani MM, Vinelli E, Kirchhoff LV et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion49, 1076–1082 (2009).
   PubMedGoogle Scholar
• Benvenuti LA, Roggério A, Freitas HF, Mansur AJ, Fiorelli A, Higuchi ML. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann. Trop. Med. Parasitol.102, 481–487 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis MD, Ma J, Yeo M, Carrasco HJ, Llewellyn MS, Miles MA. Genotyping of Trypanosoma cruzi: systematic selection of assays allowing rapid and accurate discrimination of all known lineages. Am. J. Trop. Med. Hyg.81, 1041–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease. A systematic review of observational studies. Circulation115, 1101–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Little WC et al. Development and validation of a risk for predicting mortality in Chagas’ heart disease. N. Engl. J. Med.355, 799–808 (2006).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. Chagas cardiomyopathy and ischemic stroke. Expert Rev. Cardiovasc. Ther.4(1), 119–130 (2006).
   PubMedGoogle Scholar
• Davila DF, Rossell RO, Donis JH. Cardiac parasympathetic abnormalities: cause or consequence of Chagas heart disease. Parasitol. Today5, 327–329 (1989).
   PubMedGoogle Scholar
• Rossi MA, Ramos SG. Coronary microvascular abnormalities in Chagas’ disease. Am. Heart. J.132, 207–210 (1996).
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC et al. Pathogenesis of chronic Chagas heart disease. Circulation115, 1109–1123 (2007).
   PubMed Web of Science ®Google Scholar
• Elias FE, Vigliano CA, Laguens RP, Levin MJ, Berek C. Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas’ heart disease. Am. J. Trop. Med. Hyg.68, 242–247 (2003).
   PubMed Web of Science ®Google Scholar
• Carod Artal FJ, Vargas AP, Melo M, Horan T. American trypanosomiasis (Chagas’ disease): an unrecognized cause of stroke. J. Neurol. Neurosurg. Psychiatry74, 516–518 (2003).
   PubMedGoogle Scholar
• Leon-Sarmiento FE, Mendoza E, Torres-Hillera M et al.Trypanosoma cruzi-associated cerebrovascular disease: a case–control study in Eastern Colombia. J. Neurol. Sci.217, 61–64 (2004).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. Stroke: a neglected complication of American trypanosomiasis (Chagas’ disease). Trans. R. Soc. Trop. Med. Hyg.101, 1075–1080 (2007).
   PubMed Web of Science ®Google Scholar
• Del Brutto OH, Carod-Artal FJ, Román GC et al. Stroke in the tropics. In: Tropical Neurology. American Academy of Neurology (Ed.). Lippincott Williams & Wilkins, PA, USA, 11–35 (2002).
   Google Scholar
• Pittella JE. Central nervous system involvement in Chagas disease: a hundred-year-old history. Trans. R. Soc. Trop. Med. Hyg.103, 973–978 (2009).
   PubMed Web of Science ®Google Scholar
• Aras R, da Matta JAM, Mota G, Gomes I, Melo A. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq. Bras. Cardiol.81, 414–416 (2003).
   PubMedGoogle Scholar
• Oliveira-Filho J, Viana LC, Vieira de Melo RM et al. Chagas disease is an independent risk factor for stroke: baseline characteristics of a chagas disease cohort. Stroke36, 2015–2017 (2005).
   PubMedGoogle Scholar
• Paixão LC, Ribeiro AL, Valacio RA et al. Chagas disease. Independent risk factor for stroke. Stroke40(12), 3691–3694 (2009).
   PubMed Web of Science ®Google Scholar
• Bestetti R. Stroke in a hospital-derived cohort of patients with chronic Chagas’ disease. Acta Cardiol.55, 33–38 (2000).
   PubMed Web of Science ®Google Scholar
• Nunes MCP, Barbosa MM, Ribeiro ALP, Barbosa FBL, Rocha MOC. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J. Neurol. Sci.278, 96–101 (2009).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Ribeiro Lda S, Vargas AP. Awareness of stroke risk in chagasic stroke patients. J. Neurol. Sci.263, 35–39 (2007).
   PubMed Web of Science ®Google Scholar
• Viotti RJ, Vigliano C, Laucella S et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart90, 655–660 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira JSM, Araujo RLC, Navarro MA et al. Cardiac thrombosis and thromboembolism in chronic Chagas’ heart disease. Am. J. Cardiol.2, 147–151 (1983).
   Google Scholar
• Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke36, 965–970 (2005).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Horan TA, Vargas AP, Ribeiro LS, Mamare EM. Cardioembolic stroke and ischemic small bowel infarction in a Chagas’ disease patient. Eur. J. Neurol.14, e8 (2007).
   Google Scholar
• Carod-Artal FJ, Melo M, Vargas AP. Ictus cardioembólico en la enfermedad de Chagas. Rev. Neurol.33, 311–315 (2001).
   PubMedGoogle Scholar
• Carod-Artal FJ, Vargas AP, Melo M et al. Síndrome de la oclusión rostral de la arteria basilar y enfermedad de Chagas. Rev. Neurol.35, 337–341 (2002).
   PubMedGoogle Scholar
• Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation88, 107–115 (1993).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano CA, Alvarez MG et al. The impact of socioeconomic conditions on chronic Chagas disease progression. Rev. Esp. Cardiol.62, 1224–1232 (2009).
   PubMed Web of Science ®Google Scholar
• Wackermann PV, Franca Fernandes RM, Elias J Jr et al. Involvement of the central nervous system in the chronic form of Chagas’ disease. J. Neurol. Sciences269, 152–157 (2008).
   PubMed Web of Science ®Google Scholar
• Oliveira-Filho J, Vieira de Melo RM, Reis PSO et al. Chagas disease is independently associated with brain atrophy. J. Neurol.256, 1363–1365 (2009).
   PubMedGoogle Scholar
• Lima-Costa NF, Castro-Costa E, Uchoa E et al. A population-based study of the association between Trypanosoma cruzi infection and cognitive impairment in old age (the Bambuí study). Neuroepidemiology32, 122–128 (2009).
   PubMedGoogle Scholar
• Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocide therapy for chronic asymptomatic Trypanosoma cruzi infection: a systematic review. Cochrane Database Syst. Rev.1, CD003463 (2002).
   Google Scholar
• Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA298, 2171–2181 (2009).
   Google Scholar
• Castro JA, Montalto de Mecca M, Bartel LC. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum. Exp. Toxicol.25, 471–479 (2006).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti. Infect. Ther.7(2), 157–163 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Bournissen F, Altcheh J, Panchaud A, Ito S. Is use of nifurtimox for the treatment of Chagas disease compatible with breastfeeding? A population pharmacokinetics analysis. Arch. Dis. Child.95(3), 224–228 (2010).
   PubMedGoogle Scholar
• Ribeiro I, Sevcsik AM, Alves F et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl. Trop. Dis.3, e484 (2009).
   PubMed Web of Science ®Google Scholar
• Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv. Exp. Med. Biol.625, 61–80 (2008).
   PubMedGoogle Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. DOI: 10.1016/j.actatropica.2009.10.023 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Garcia S, Ramos CO, Senra JFV et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob. Agents Chemother.49, 1521–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine. Expert Rev. Anti. Infect. Ther.5(4), 717–726 (2007).
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr. Opin. Infect. Dis.19, 583–587 (2006).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med.144, 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Reyes PA, Vallejo M. Trypanocide drugs for the late stage, symptomatic CD (Trypanosoma cruzi infection). Cochrane Database Syst. Rev.4, CD004102 (2005).
   Google Scholar
• Marin-Neto JA, Rassi A, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the benznidazole evaluation for interrupting trypanosomiais (BENEFIT). Am. Heart J.156, 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke37, 577–617 (2006).
   PubMed Web of Science ®Google Scholar
• Derex L, Nighoghossian N, Perinetti M, Honnorat J, Trouillas P. Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus. Neurology57, 2122–2125 (2001).
   PubMed Web of Science ®Google Scholar
• Trabuco CC, Pereira de Jesus PA, Bacellar AS, Oliveira-Filho J. Successful thrombolysis in cardioembolic stroke from Chagas disease. Neurology62, 170–171 (2005).
   Google Scholar
• Dubner S, Schapachnik E, Riera AR, Valero E. Chagas disease: state-of-the-art of diagnosis and management. Cardiol. J.15, 493–504 (2008).
   PubMedGoogle Scholar
• Carod-Artal FJ. Some reflections on stroke treatment in South America. Rev. Neurol.44, 257–258 (2007).
   PubMedGoogle Scholar
• Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet375(9709), 148–159 (2009).
   PubMed Web of Science ®Google Scholar
• Smith DH, Pepin J, Stich AHR. Human African trypanosomiasis: an emerging public health crisis. Br. Med. J.54, 341–355 (1998).
   Google Scholar
• WHO. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol. Rec.8, 71–80 (2006).
   Google Scholar
• Lejon V, Boelaert M, Jannin J, Moore A, Buscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness outside Africa. Lancet Infect. Dis.3, 804–808 (2003).
   PubMedGoogle Scholar
• Jelinek T, Bisoffi Z, Bonazzi L et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg. Infect. Dis.8, 634–635 (2002).
   PubMed Web of Science ®Google Scholar
• Moore AC, Ryan ET, Waldron MA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20–2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa. N. Engl. J. Med.346, 2069–2076 (2002).
   PubMedGoogle Scholar
• Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop.97, 55–64 (2006).
   PubMedGoogle Scholar
• Kennedy PG. Human African trypanosomiasis: neurological aspects. J. Neurol.253, 411–416 (2006).
   PubMedGoogle Scholar
• Blum JA, Zellweger MJ, Burri C, Hatz C. Cardiac involvement in African and American trypanosomiasis. Lancet Infect. Dis.8, 631–641 (2008).
   PubMed Web of Science ®Google Scholar
• Blum JA, Burri C, Hatz C, Kazumba L, Mangoni P, Zellweger MJ. Sleeping hearts: the role of the heart in sleeping sickness (human African tryopanosomiasis). Trop. Med. Int. Health12, 1422–1432 (2007).
   PubMed Web of Science ®Google Scholar
• Poltera AA, Hochmann A, Lambert PH. A model for cardiopathy induced by Trypanosoma brucei brucei in mice. A histologic and immunopathologic study. Am. J. Pathol.99, 325–352 (1980).
   PubMedGoogle Scholar
• Collomb H, Bartoli D. The heart in human African trypanosomiasis caused by Trypanosoma gambiense. Bull. Soc. Pathol. Exot. Filiales60, 142–156 (1967).
   PubMedGoogle Scholar
• Blum JA, Schmid C, Burri C et al. Cardiac alterations in Human African Trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl. Trop. Dis.3, e383 (2009).
   PubMed Web of Science ®Google Scholar
• Damian MS, Dorndof W, Burkardt H, Singer I, Leinweber B, Schachenmayr W. Polyneuritis and myositis in Trypanosoma gambiense infection. Dtsch Med. Wochenschr.119, 1690–1693 (1994).
   PubMedGoogle Scholar
• Croft AM, Jackson CJ, Friend HM, Minton EJ. African trypanosomiasis in a British soldier. J. R. Army Med. Corps152, 156–160 (2006).
   PubMedGoogle Scholar
• Tsala MP, Blackett K, Mbonifor CL, Leke R, Etoundi J. Functional and immunologic involvement in human African tryopanosomiasis caused by Trypanosoma gambiense. Bull. Soc. Pathol. Exot. Filiales81, 490–501 (1988).
   PubMedGoogle Scholar
• Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol.152, 1155–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Priotto G, Pinoges L, Fursa IB et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. Br. Med. J.336, 679–680 (2008).
   PubMedGoogle Scholar
• Blum J, Nkunku S, Burri C. Clinical description of encephalophathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health6, 390–400 (2001).
   PubMed Web of Science ®Google Scholar
• Chappuis F. Melarsoprol-free drug combinations for second stage Gambian sleeping sickness: the way to go. Clin. Infect. Dis.45, 1443–1445 (2007).
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Mutombo W et al. Nifurtimox–eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, Phase III, non-inferiority trial. Lancet374, 56–64 (2009).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. Chagas disease and stroke. Lancet Neurol.9, 533–542 (2010).
   PubMed Web of Science ®Google Scholar